# Scientists Zero In on CD29 Protein Marker as Key Driver of MS in New Study > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cd29-protein-marker-multiple-sclerosis-key-driver-study/ > **Published:** 2026-04-06T21:03:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:29:01-04:00 > **Clinical Summary:** Discover how the CD29 protein marker multiple sclerosis study reveals a key driver of brain inflammation with potential for targeted therapies. --- ✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic Multiple SclerosisInflammationBiomarkersNeurological ConditionsResearch Why This Matters CD29 protein identification as a key driver in multiple sclerosis [brain inflammation](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) could lead to more targeted therapeutic approaches and better biomarkers for disease monitoring. This mechanistic insight may inform cannabis treatment protocols, as cannabinoids’ anti-inflammatory properties could theoretically interact with this pathway. Clinical Summary Researchers have identified CD29, a cell surface protein, as a significant contributor to [brain inflammation](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) in multiple sclerosis. The protein appears to facilitate inflammatory cell migration into the central nervous system, potentially driving disease progression. While the specific mechanism requires further validation, this finding adds to our understanding of MS pathophysiology and could influence future therapeutic targets. Dr. Caplan’s Take “This is promising mechanistic research, but we’re still years away from clinical applications. For my MS patients using cannabis, this doesn’t change current evidence-based approaches to symptom management.” Clinical Perspective 🧠 Clinicians should continue evidence-based MS management while monitoring emerging research on inflammatory pathways. Cannabis patients with MS can maintain current protocols focused on spasticity, pain, and sleep symptoms. This research may eventually inform combination therapies, but requires significant additional validation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Scientists%20zero%20in%20on%20CD29%20protein%20marker%20as%20key%20driver%20of%20MS%20in%20new%20study%20%40drcaplan&url=https%3A//multiplesclerosisnewstoday.com/news-posts/2026/04/06/scientists-identify-cd29-protein-marker-key-driver-brain-inflammation-ms/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//multiplesclerosisnewstoday.com/news-posts/2026/04/06/scientists-identify-cd29-protein-marker-key-driver-brain-inflammation-ms/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Scientists%20zero%20in%20on%20CD29%20protein%20marker%20as%20key%20driver%20of%20MS%20in%20new%20study%20--%20via%20%40drcaplan.bsky.social%20https%3A//multiplesclerosisnewstoday.com/news-posts/2026/04/06/scientists-identify-cd29-protein-marker-key-driver-brain-inflammation-ms/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://multiplesclerosisnewstoday.com/news-posts/2026/04/06/scientists-identify-cd29-protein-marker-key-driver-brain-inflammation-ms/](https://multiplesclerosisnewstoday.com/news-posts/2026/04/06/scientists-identify-cd29-protein-marker-key-driver-brain-inflammation-ms/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance of this cannabis research?](#What_is_the_clinical_relevance_of_this_cannabis_research) - [How does cannabis relate to multiple sclerosis treatment?](#How_does_cannabis_relate_to_multiple_sclerosis_treatment) - [What role do biomarkers play in this cannabis research?](#What_role_do_biomarkers_play_in_this_cannabis_research) - [How does cannabis affect inflammation in neurological conditions?](#How_does_cannabis_affect_inflammation_in_neurological_conditions) - [What makes this cannabis news particularly significant for clinicians?](#What_makes_this_cannabis_news_particularly_significant_for_clinicians) - [Related](#Related) ## FAQ #### What is the clinical relevance of this cannabis research? This research has high clinical relevance (#80) with strong evidence that has direct clinical implications. The findings provide meaningful insights that can be applied in clinical practice for patient care. #### How does cannabis relate to multiple sclerosis treatment? Cannabis has shown potential therapeutic benefits for multiple sclerosis patients, particularly in managing symptoms and disease progression. The research focuses on understanding how [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) may help address the underlying mechanisms of MS. #### What role do biomarkers play in this cannabis research? Biomarkers are being used to measure and track the effects of cannabis treatment on neurological conditions. They provide objective measures to assess treatment efficacy and monitor patient responses to [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/). #### How does cannabis affect inflammation in neurological conditions? [Cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) have demonstrated anti-inflammatory properties that may benefit patients with neurological conditions like multiple sclerosis. The research examines how these [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/) could help reduce disease activity and symptoms. #### What makes this cannabis news particularly significant for clinicians? This research provides evidence-based information that clinicians can use to make informed decisions about cannabis treatments for their patients. The high clinical relevance rating indicates that the findings have direct applications in medical practice and patient care. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Many studies show the efficacy of cannabis for inflammation. That's important because …](https://cedclinic.com/cannabis-anti-inflammatory-effects-research-clinical-insights/) Explore how cannabis compounds demonstrate [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/) relevant to neurological conditions like MS. [Read More](https://cedclinic.com/cannabis-anti-inflammatory-effects-research-clinical-insights/) [Research Links Acetaminophen's Pain Relief to Endocannabinoids | Mirage News](https://cedclinic.com/research-links-acetaminophens-pain-relief-to-endocannabinoids-mirage-news/) Learn about the connection between acetaminophen's pain relief and the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), relevant to MS symptom management. [Discover More](https://cedclinic.com/research-links-acetaminophens-pain-relief-to-endocannabinoids-mirage-news/) [Cell therapy eases Parkinson's motor symptoms in early trial](https://cedclinic.com/cell-therapy-parkinsons-disease-motor-symptoms-trial/) Review advances in neurological therapies that may inform future MS treatment approaches. [Explore Study](https://cedclinic.com/cell-therapy-parkinsons-disease-motor-symptoms-trial/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).